Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha
Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1988 |
|---|
| Umfang: |
5 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Annals of hematology - 1955, 56(1988) vom: Feb., Seite 87-91 |
| Übergeordnetes Werk: |
volume:56 ; year:1988 ; month:02 ; pages:87-91 ; extent:5 |
| Links: |
|---|
| Katalog-ID: |
NLEJ202964442 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ202964442 | ||
| 003 | DE-627 | ||
| 005 | 20230505233617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1988 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ202964442 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha |
| 264 | 1 | |c 1988 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Hehlmann, R. |4 oth | |
| 700 | 1 | |a Anger, B. |4 oth | |
| 700 | 1 | |a Messerer, D. |4 oth | |
| 700 | 1 | |a Zankovich, R. |4 oth | |
| 700 | 1 | |a Bergmann, L. |4 oth | |
| 700 | 1 | |a Kolb, H. J. |4 oth | |
| 700 | 1 | |a Meyer, P. |4 oth | |
| 700 | 1 | |a Essers, U. |4 oth | |
| 700 | 1 | |a Queißer, U. |4 oth | |
| 700 | 1 | |a Vaupel, H. |4 oth | |
| 700 | 1 | |a Walther, F. |4 oth | |
| 700 | 1 | |a Hossfeld, D. K. |4 oth | |
| 700 | 1 | |a Zimmermann, R. |4 oth | |
| 700 | 1 | |a Heiss, F. |4 oth | |
| 700 | 1 | |a Mende, S. |4 oth | |
| 700 | 1 | |a Tigges, F. J. |4 oth | |
| 700 | 1 | |a Kleeberg, U. R. |4 oth | |
| 700 | 1 | |a Pralle, H. |4 oth | |
| 700 | 1 | |a Kayser, W. |4 oth | |
| 700 | 1 | |a Tichelli, A. |4 oth | |
| 700 | 1 | |a Faulhaber, J. D. |4 oth | |
| 700 | 1 | |a Räth, U. |4 oth | |
| 700 | 1 | |a Schubert, H. |4 oth | |
| 700 | 1 | |a Bross, K. |4 oth | |
| 700 | 1 | |a Schlag, R. |4 oth | |
| 700 | 1 | |a Schmid, L. |4 oth | |
| 700 | 1 | |a Weißenfels, I. |4 oth | |
| 700 | 1 | |a Heinze, B. |4 oth | |
| 700 | 1 | |a Georgii, A. |4 oth | |
| 700 | 1 | |a Queißer, W. |4 oth | |
| 700 | 1 | |a Heimpel, H. |4 oth | |
| 773 | 0 | 8 | |i in |t Annals of hematology |d 1955 |g 56(1988) vom: Feb., Seite 87-91 |w (DE-627)NLEJ18898836X |w (DE-600)1458429-3 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:1988 |g month:02 |g pages:87-91 |g extent:5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF00633471 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 1988 |c 2 |h 87-91 |g 5 | ||
| matchkey_str |
article:14320584:1988----::admzdtdoteramnocrncylilueiclnhoipaeihuufnessy |
|---|---|
| hierarchy_sort_str |
1988 |
| publishDate |
1988 |
| allfields |
(DE-627)NLEJ202964442 DE-627 ger DE-627 rakwb eng Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha 1988 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML. Springer Online Journal Archives 1860-2002 Hehlmann, R. oth Anger, B. oth Messerer, D. oth Zankovich, R. oth Bergmann, L. oth Kolb, H. J. oth Meyer, P. oth Essers, U. oth Queißer, U. oth Vaupel, H. oth Walther, F. oth Hossfeld, D. K. oth Zimmermann, R. oth Heiss, F. oth Mende, S. oth Tigges, F. J. oth Kleeberg, U. R. oth Pralle, H. oth Kayser, W. oth Tichelli, A. oth Faulhaber, J. D. oth Räth, U. oth Schubert, H. oth Bross, K. oth Schlag, R. oth Schmid, L. oth Weißenfels, I. oth Heinze, B. oth Georgii, A. oth Queißer, W. oth Heimpel, H. oth in Annals of hematology 1955 56(1988) vom: Feb., Seite 87-91 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:56 year:1988 month:02 pages:87-91 extent:5 http://dx.doi.org/10.1007/BF00633471 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 56 1988 2 87-91 5 |
| spelling |
(DE-627)NLEJ202964442 DE-627 ger DE-627 rakwb eng Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha 1988 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML. Springer Online Journal Archives 1860-2002 Hehlmann, R. oth Anger, B. oth Messerer, D. oth Zankovich, R. oth Bergmann, L. oth Kolb, H. J. oth Meyer, P. oth Essers, U. oth Queißer, U. oth Vaupel, H. oth Walther, F. oth Hossfeld, D. K. oth Zimmermann, R. oth Heiss, F. oth Mende, S. oth Tigges, F. J. oth Kleeberg, U. R. oth Pralle, H. oth Kayser, W. oth Tichelli, A. oth Faulhaber, J. D. oth Räth, U. oth Schubert, H. oth Bross, K. oth Schlag, R. oth Schmid, L. oth Weißenfels, I. oth Heinze, B. oth Georgii, A. oth Queißer, W. oth Heimpel, H. oth in Annals of hematology 1955 56(1988) vom: Feb., Seite 87-91 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:56 year:1988 month:02 pages:87-91 extent:5 http://dx.doi.org/10.1007/BF00633471 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 56 1988 2 87-91 5 |
| allfields_unstemmed |
(DE-627)NLEJ202964442 DE-627 ger DE-627 rakwb eng Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha 1988 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML. Springer Online Journal Archives 1860-2002 Hehlmann, R. oth Anger, B. oth Messerer, D. oth Zankovich, R. oth Bergmann, L. oth Kolb, H. J. oth Meyer, P. oth Essers, U. oth Queißer, U. oth Vaupel, H. oth Walther, F. oth Hossfeld, D. K. oth Zimmermann, R. oth Heiss, F. oth Mende, S. oth Tigges, F. J. oth Kleeberg, U. R. oth Pralle, H. oth Kayser, W. oth Tichelli, A. oth Faulhaber, J. D. oth Räth, U. oth Schubert, H. oth Bross, K. oth Schlag, R. oth Schmid, L. oth Weißenfels, I. oth Heinze, B. oth Georgii, A. oth Queißer, W. oth Heimpel, H. oth in Annals of hematology 1955 56(1988) vom: Feb., Seite 87-91 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:56 year:1988 month:02 pages:87-91 extent:5 http://dx.doi.org/10.1007/BF00633471 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 56 1988 2 87-91 5 |
| allfieldsGer |
(DE-627)NLEJ202964442 DE-627 ger DE-627 rakwb eng Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha 1988 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML. Springer Online Journal Archives 1860-2002 Hehlmann, R. oth Anger, B. oth Messerer, D. oth Zankovich, R. oth Bergmann, L. oth Kolb, H. J. oth Meyer, P. oth Essers, U. oth Queißer, U. oth Vaupel, H. oth Walther, F. oth Hossfeld, D. K. oth Zimmermann, R. oth Heiss, F. oth Mende, S. oth Tigges, F. J. oth Kleeberg, U. R. oth Pralle, H. oth Kayser, W. oth Tichelli, A. oth Faulhaber, J. D. oth Räth, U. oth Schubert, H. oth Bross, K. oth Schlag, R. oth Schmid, L. oth Weißenfels, I. oth Heinze, B. oth Georgii, A. oth Queißer, W. oth Heimpel, H. oth in Annals of hematology 1955 56(1988) vom: Feb., Seite 87-91 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:56 year:1988 month:02 pages:87-91 extent:5 http://dx.doi.org/10.1007/BF00633471 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 56 1988 2 87-91 5 |
| allfieldsSound |
(DE-627)NLEJ202964442 DE-627 ger DE-627 rakwb eng Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha 1988 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML. Springer Online Journal Archives 1860-2002 Hehlmann, R. oth Anger, B. oth Messerer, D. oth Zankovich, R. oth Bergmann, L. oth Kolb, H. J. oth Meyer, P. oth Essers, U. oth Queißer, U. oth Vaupel, H. oth Walther, F. oth Hossfeld, D. K. oth Zimmermann, R. oth Heiss, F. oth Mende, S. oth Tigges, F. J. oth Kleeberg, U. R. oth Pralle, H. oth Kayser, W. oth Tichelli, A. oth Faulhaber, J. D. oth Räth, U. oth Schubert, H. oth Bross, K. oth Schlag, R. oth Schmid, L. oth Weißenfels, I. oth Heinze, B. oth Georgii, A. oth Queißer, W. oth Heimpel, H. oth in Annals of hematology 1955 56(1988) vom: Feb., Seite 87-91 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:56 year:1988 month:02 pages:87-91 extent:5 http://dx.doi.org/10.1007/BF00633471 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 56 1988 2 87-91 5 |
| language |
English |
| source |
in Annals of hematology 56(1988) vom: Feb., Seite 87-91 volume:56 year:1988 month:02 pages:87-91 extent:5 |
| sourceStr |
in Annals of hematology 56(1988) vom: Feb., Seite 87-91 volume:56 year:1988 month:02 pages:87-91 extent:5 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Annals of hematology |
| authorswithroles_txt_mv |
Hehlmann, R. @@oth@@ Anger, B. @@oth@@ Messerer, D. @@oth@@ Zankovich, R. @@oth@@ Bergmann, L. @@oth@@ Kolb, H. J. @@oth@@ Meyer, P. @@oth@@ Essers, U. @@oth@@ Queißer, U. @@oth@@ Vaupel, H. @@oth@@ Walther, F. @@oth@@ Hossfeld, D. K. @@oth@@ Zimmermann, R. @@oth@@ Heiss, F. @@oth@@ Mende, S. @@oth@@ Tigges, F. J. @@oth@@ Kleeberg, U. R. @@oth@@ Pralle, H. @@oth@@ Kayser, W. @@oth@@ Tichelli, A. @@oth@@ Faulhaber, J. D. @@oth@@ Räth, U. @@oth@@ Schubert, H. @@oth@@ Bross, K. @@oth@@ Schlag, R. @@oth@@ Schmid, L. @@oth@@ Weißenfels, I. @@oth@@ Heinze, B. @@oth@@ Georgii, A. @@oth@@ Queißer, W. @@oth@@ Heimpel, H. @@oth@@ |
| publishDateDaySort_date |
1988-02-01T00:00:00Z |
| hierarchy_top_id |
NLEJ18898836X |
| id |
NLEJ202964442 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202964442</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505233617.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1988 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202964442</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1988</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hehlmann, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Anger, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Messerer, D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zankovich, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bergmann, L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kolb, H. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meyer, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Essers, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Queißer, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vaupel, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Walther, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hossfeld, D. K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zimmermann, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heiss, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mende, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tigges, F. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kleeberg, U. R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pralle, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kayser, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tichelli, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Faulhaber, J. D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Räth, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schubert, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bross, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schlag, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmid, L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weißenfels, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heinze, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Georgii, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Queißer, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heimpel, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">56(1988) vom: Feb., Seite 87-91</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:56</subfield><subfield code="g">year:1988</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:87-91</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00633471</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">56</subfield><subfield code="j">1988</subfield><subfield code="c">2</subfield><subfield code="h">87-91</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ18898836X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-0584 |
| topic_title |
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r h rh b a ba d m dm r z rz l b lb h j k hj hjk p m pm u e ue u q uq h v hv f w fw d k h dk dkh r z rz f h fh s m sm f j t fj fjt u r k ur urk h p hp w k wk a t at j d f jd jdf u r ur h s hs k b kb r s rs l s ls i w iw b h bh a g ag w q wq h h hh |
| hierarchy_parent_title |
Annals of hematology |
| hierarchy_parent_id |
NLEJ18898836X |
| hierarchy_top_title |
Annals of hematology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ18898836X (DE-600)1458429-3 |
| title |
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha |
| spellingShingle |
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha |
| ctrlnum |
(DE-627)NLEJ202964442 |
| title_full |
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha |
| journal |
Annals of hematology |
| journalStr |
Annals of hematology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1988 |
| contenttype_str_mv |
zzz |
| container_start_page |
87 |
| container_volume |
56 |
| physical |
5 |
| format_se |
Elektronische Aufsätze |
| title_sort |
randomized study on the treatment of chronic myeloid leukemia (cml) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha |
| title_auth |
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha |
| abstract |
Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML. |
| abstractGer |
Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML. |
| abstract_unstemmed |
Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha |
| url |
http://dx.doi.org/10.1007/BF00633471 |
| remote_bool |
true |
| author2 |
Hehlmann, R. Anger, B. Messerer, D. Zankovich, R. Bergmann, L. Kolb, H. J. Meyer, P. Essers, U. Queißer, U. Vaupel, H. Walther, F. Hossfeld, D. K. Zimmermann, R. Heiss, F. Mende, S. Tigges, F. J. Kleeberg, U. R. Pralle, H. Kayser, W. Tichelli, A. Faulhaber, J. D. Räth, U. Schubert, H. Bross, K. Schlag, R. Schmid, L. Weißenfels, I. Heinze, B. Georgii, A. Queißer, W. Heimpel, H. |
| author2Str |
Hehlmann, R. Anger, B. Messerer, D. Zankovich, R. Bergmann, L. Kolb, H. J. Meyer, P. Essers, U. Queißer, U. Vaupel, H. Walther, F. Hossfeld, D. K. Zimmermann, R. Heiss, F. Mende, S. Tigges, F. J. Kleeberg, U. R. Pralle, H. Kayser, W. Tichelli, A. Faulhaber, J. D. Räth, U. Schubert, H. Bross, K. Schlag, R. Schmid, L. Weißenfels, I. Heinze, B. Georgii, A. Queißer, W. Heimpel, H. |
| ppnlink |
NLEJ18898836X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| up_date |
2024-07-06T09:23:44.223Z |
| _version_ |
1803821068292456448 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202964442</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505233617.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1988 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202964442</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1988</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia positive CML. Additional goals are the examination of whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By December 31, 1987, 326 CML-patients had been randomized, 150 for busulfan, 150 for hydroxyurea and 26 for interferon-alpha. The average age is 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hehlmann, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Anger, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Messerer, D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zankovich, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bergmann, L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kolb, H. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meyer, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Essers, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Queißer, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vaupel, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Walther, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hossfeld, D. K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zimmermann, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heiss, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mende, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tigges, F. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kleeberg, U. R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pralle, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kayser, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tichelli, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Faulhaber, J. D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Räth, U.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schubert, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bross, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schlag, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmid, L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weißenfels, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heinze, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Georgii, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Queißer, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heimpel, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">56(1988) vom: Feb., Seite 87-91</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:56</subfield><subfield code="g">year:1988</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:87-91</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00633471</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">56</subfield><subfield code="j">1988</subfield><subfield code="c">2</subfield><subfield code="h">87-91</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| score |
7.400099 |